Adjuvant chemotherapy for early-stage non-small cell lung cancer: The past, the present and the future

Research output: Contribution to journalReview article

4 Scopus citations


Complete resection is mandatory in order to achieve a cure in patients with early-stage non-small cell lung cancer (NSCLC). However, despite complete resection, a substantial proportion of patients have disease recurrence, with distant metastases being the primary sites of failure. Recent trials have conclusively demonstrated the benefit of platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC. The role of adjuvant chemotherapy in resected stage III NSCLC is less clear, with trials showing conflicting results. The role of targeted agents in this setting is being investigated. Gene expression profiling studies should help direct chemotherapy to those who would actually benefit from it, thereby saving others from unnecessary toxicity.

Original languageEnglish (US)
Pages (from-to)709-716
Number of pages8
JournalExpert Opinion on Biological Therapy
Issue number7
StatePublished - Jul 1 2006



  • Adjuvant
  • Early stage
  • Lung cancer
  • Outcome
  • Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this